Tolerogenic dendritic cells
By M. Takenaka, F. Quintana. Seminars in Immunopathology, 2016
647 citations recorded by the source corpus.
Deficits in immunological tolerance against self-antigens and antigens provided by the diet and commensal microbiota can result in the development of inflammatory and autoimmune disorders. Dendritic cells (DCs) are pivotal regulators of the immune response, specialized in antigen presentation to drive T cell priming and differentiation. DCs also have a tolerogenic function, participating in the enforcement of central and peripheral tolerance and the resolution of ongoing immune responses. Thus, DCs control effector and regulatory mechanisms relevant to the pathology of autoimmune disorders. In this review, we discuss recent findings regarding the control of the adaptive immune response by tolerogenic DCs. A thorough understanding of the mechanisms that control the tolerogenic DC phenotype will guide the development of novel strategies for the treatment of autoimmunity.
Subfields: Immunology
View Paper: https://www.semanticscholar.org/paper/2cfacf8dfde1ea7bdad20b6b8c351905befbd25e
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Immunology
Citations in the corpus
- Tumor-associated stromal cells as key contributors to the tumor microenvironment (2016, background): “Dendritic cell activity is frequently dysregulated in cancer, leading to reduction in mature dendritic cell numbers, abnormal maturation (and increased numbers of immature dendritic cells with tolerogenic and immunosuppressive capabilities), and suppressed differentiation [28].”
- Tolerance and Exhaustion: Defining Mechanisms of T cell Dysfunction (2013, positive): “T cell fate following peripheral encounter with self-antigen is partly dictated by the activation state of the antigen-presenting cell (APC) [17,18]: T cells encountering selfantigen presented by non-activated or non-professional APCs receive incomplete priming signals, and either undergo programmed”
- The Tumor Microenvironment Innately Modulates Cancer Progression (2019, neutral): “CD115, CD107b, FceRI, CD80, CD86 Antitumor (19, 95, 97, 99, 100)”